There is no evidence that taking hydroxychloroquine (Plaquenil) is effective in preventing a person from contracting the coronavirus (COVID-19). People with lupus should follow the guidance of their doctor and the safety guidelines being issued by the CDC.
Lupus is a chronic autoimmune disease — that means that the immune system is dysfunctional and attacks one’s healthy tissue. This can make the immune system less effective at fighting infections. Medications that suppress the immune system — which people with lupus often take — can also limit their body’s ability to respond to infections. As a result, people with lupus are less able to fight off bacteria and viruses, like COVID-19. When people with lupus do get sick their illness may also trigger a lupus flare. People with lupus may also have other conditions that put them at higher risk for serious illness from coronavirus such as diabetes, cardiovascular disease, kidney disease, and a weakened immune system.
Few AIM-listed drug development companies have late-stage clinical assets in the pipeline, ImmuPharma plc (LON:IMM) is an exception. The Company’s lead compound, Lupuzor™, a potential treatment for Lupus, has completed Phase 3 trial of dosing patients across the US, Europe and Mauritius with top line results announced.